Privia Health's reaffirmation of its FY24 revenue guidance, which is substantially below the estimated expectations, could lead to negative investor sentiment and potentially impact the stock price negatively in the short term. The significant discrepancy between the company's guidance and market expectations may raise concerns about growth prospects and operational challenges.